SAN DIEGO, Sept. 25, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released the latest episode of its Science Bytes podcast, featuring Dr. Terry O'Neil, President and Medical Director of Urgent Care Pros.
In Episode 51, Through the Shades of Illness, Testing Brings Clarity, Dr. O'Neil discusses how respiratory illnesses often present with overlapping symptoms, making it difficult to distinguish one condition from another without testing. Drawing on more than 20 years of emergency and urgent care experience, he explains how timely, accurate diagnostics not only guide treatment decisions but also protect families and communities from spread.
Key points from Dr. O'Neil's discussion include:
This episode highlights the vital role urgent care centers play in respiratory season by offering immediate access to testing and treatment when primary care or emergency departments may not be readily available.
The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact: Juliet Cunningham Vice President, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$26.40 |
Daily Change: | 0.09 0.34 |
Daily Volume: | 380,340 |
Market Cap: | US$1.790B |
September 22, 2025 August 19, 2025 August 13, 2025 August 05, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load